Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

Summary

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.

Timeline

Start

2024-10-10

Primary completion

2025-09-26

Completion

2025-09-26

Outcome

Met primary endpoint

release “the Phase 2a clinical trial of RAP-219 (RAP-219-FOS-201) in patients with drug-resistant focal onset seizures met its primary endpoint” rapportrx.com ↗

release “Phase 2a clinical trial of RAP-219 in patients with drug-resistant FOS (n=30) met its primary long episode (LE) endpoints with high statistical significance” rapportrx.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RAP-219	Unknown	1.25 mg	Oral

Indications